Boston Partners Acquires Shares of 1,028,745 Organon & Co. (NYSE:OGN)

Boston Partners acquired a new position in shares of Organon & Co. (NYSE:OGN) during the first quarter, Holdings Channel.com reports. The fund acquired 1,028,745 shares of the company’s stock, valued at approximately $19,306,000.

Several other institutional investors and hedge funds have also recently modified their holdings of OGN. Lindbrook Capital LLC raised its holdings in Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after acquiring an additional 1,428 shares during the last quarter. Gladius Capital Management LP grew its stake in Organon & Co. by 65.1% in the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after purchasing an additional 858 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in Organon & Co. in the 1st quarter worth approximately $43,000. Tompkins Financial Corp raised its stake in shares of Organon & Co. by 450.7% in the first quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after purchasing an additional 1,974 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of Organon & Co. during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on OGN. Piper Sandler boosted their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. The Goldman Sachs Group boosted their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd.

Organon & Co. Trading Down 3.4 %

Organon & Co. stock traded down $0.74 during midday trading on Friday, reaching $20.91. The stock had a trading volume of 2,064,114 shares, compared to its average volume of 1,489,019. The stock’s 50-day simple moving average is $20.89 and its 200 day simple moving average is $19.19. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. The stock has a market capitalization of $5.38 billion, a PE ratio of 5.11, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Analysts expect that Organon & Co. will post 4.25 EPS for the current year.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.